Founded at the Abramson Cancer Center at the University of Pennsylvania

Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

Journal of Clinical Oncology | 2020

Dmitriy Zamarin, MD, PhD; Robert A. Burger, MD; Michael W. Sill, PhD; Daniel J. Powell Jr, PhD; Heather A. Lankes, PhD, MPH; Michael D. Feldman, MD, PhD; Oliver Zivanovic, MD, PhD; Camille Gunderson, MD; Emily Ko, MD, MSCR; Cara Mathews, MD; Sudarshan Sharma, MD; Andrea R. Hagemann, MD; Samir Khleif, MD; Carol Aghajanian, MD